Fruquintinib, an oral agent that targets the vascular endothelial growth factor (VEGF) pathway, has shown promise in treating metastatic colorectal cancer, particularly in those who have exhausted standard chemotherapy options and have failed to show improvement (4, 5). This evidence concerns the gene VEGFA and metastatic colorectal cancer.